JNK Signaling Pathway response and stable disease in two patients

8 1 cycle of Three patients in JNK Signaling Pathway stratum A re U 140 mg / day dasatinib, a patient has once again U 180 mg / day and two patients had again U 210 mg / day. Re for Stratum B, three patients U 100 mg / day, may need during the patient dasatinib alone was 180 or 210 mg / day. Participation in pharmacokinetic studies has been recommended but not required, but contributed to limited compliance. Due to the limited data at each level of the dasatinib dose, the Cmax and AUC inf dose normalized to the effect of erlotinib and at the same rate EIAEDs on the pharmacokinetics of dasatinib as the Erh Administered increase dasatinib dose-proportional shows AUC and linear elimination characteristics in a dose range of 15 240 mg / day. In general, the dose-normalized Cmax and AUC will receive dasatinib 0 24 values in week 1, were not co-administered erlotinib in patients with low B stratum concomitant use of EIAEDs compared to those of the stratum A EIAEDs without suggesting that the CYP3A4 enzyme, a first pathway of dasatinib in humans is induced by EIAEDs. On average, Cmax and AUC0 24 levels on day 35 of cycle 1 received was 1.85 and 1.67 times h Ago than those who received w During weeks 1 to Stratum A, suggesting that dasatinib exposure is through concomitant administration of erlotinib increased ht. In stratum B, were the increase in Cmax and AUC0 24h on day 35 of cycle 1, 4.21 and 2.57 times h Higher than the w Received during the week 1 of cycle 1. This effect was probably due to the h Higher dose of erlotinib and green Ere inhibition of erlotinib clearance in the presence of dasatinib by the induction EIAED. Even with this normalized Erh Increase of the layer B, dasatinib exposure dose with erlotinib on day 35 of cycle 1 was even lower than in the general stratum A, probably due to the inductive effect of simultaneous EIAEDs CYP3A4. Results for layer A was the best response and stable disease in two patients, both of which have made progress after 4 months, and progressive disease in all others. In stratum B, nine patients had stable disease, but all were up to 6 months, with the exception of one patient who progressed after 9 months of treatment. With a median follow-up of 138.7 weeks, the median progression-free survival and PFS for all patients is 6 4.3 weeks and 2.1%. The simultaneous EIAEDs seem either not affect PFS and OS, respectively. Forward thinking clinical trials evaluating monotherapy administration of inhibitors targeting mediators of cell signaling cascades were disappointed; Traded, among unselected patients with malignant glioma to date. Combinations of drugs, the mediators of different but interacting cellular Ren inhibit signaling cascades, an attractive therapeutic strategy to achieve better results. Therefore inhibit EGFR targeting in combination with an inhibitor of a CBC Ann Approximation of activators key PI3/AKTexposure, toxicity was t in patients given ketoconazole, a known inhibitor of CYP3A were connected together erh Ht. A recent in vitro study showed that erlotinib inhibits CYP3A substratedependent in a way. Three patients in stratum A in our study that re U dasatinib 140 mg erlotinib and 150, Cmax and AUC0 24 values of dasatinib were 28 days of cycle 1 284, and 110%.